Feedback
Settings

Settings

Goto Application

2,926 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(YHRRPHCORALGKQ-FDDDBJFASA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 293
1.WO/2024/197309PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS
WO - 26.09.2024
Int.Class A61K 47/54
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
 Appl.No PCT/US2024/021351 Applicant MODERNATX, INC. Inventor SEEPERSAUD, Mohindra
Provided herein are targeting compounds (e.g., a compound of Formula I, a stereoisomer thereof, a tautomer thereof, and/or a pharmaceutically acceptable salt thereof), lipid nanoparticle (LNP) compositions comprising such targeting compounds and the use thereof. The LNP compositions described herein may further comprise one or more selected from ionizable lipids, PEG-lipids, phospholipids, and structural lipids.
2.WO/2024/194153RSV-F-ENCODING NUCLEIC ACIDS
WO - 26.09.2024
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/EP2024/056893 Applicant GLAXOSMITHKLINE BIOLOGICALS SA Inventor BARROWS, Nicholas John
The present disclosure provides inter alia, a recombinant ribonucleic acid (RNA) encoding a respiratory syncytial virus fusion (RSV-F) protein comprising an F2 and an F1 domain; wherein the RSV-F protein further comprises, relative to a wild-type RSV-F sequence, the substitution of a residue for a C residue in both of the F2 and F1 domains.
3.WO/2024/197307PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS
WO - 26.09.2024
Int.Class A61K 47/50
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
 Appl.No PCT/US2024/021344 Applicant MODERNATX, INC. Inventor SEEPERSAUD, Mohindra
Provided herein are targeting compounds (e.g., a compound of Formula I, a stereoisomer thereof, a tautomer thereof, and/or a pharmaceutically acceptable salt thereof), lipid nanoparticle (LNP) compositions comprising such targeting compounds and the use thereof. The LNP compositions described herein may further comprise one or more selected from ionizable lipids, PEG-lipids, phospholipids, and structural lipids.
4.WO/2024/193965RSV-F-ENCODING NUCLEIC ACIDS
WO - 26.09.2024
Int.Class C12N 15/45
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
45Paramyxoviridae, e.g. measles virus, mumps virus, Newcastle disease virus, canine distemper virus, rinderpest virus, respiratory syncytial viruses
 Appl.No PCT/EP2024/055127 Applicant GLAXOSMITHKLINE BIOLOGICALS SA Inventor BIANCUCCI, Marco
The present disclosure provides inter alia, a recombinant nucleic acid encoding a respiratory syncytial virus fusion (RSV-F) protein comprising a cytoplasmic tail; wherein, relative to a cytoplasmic tail according to SEQ ID NO: 3 or 4, 2-20 residues are deleted from the cytoplasmic tail of the RSV-F protein.
5.WO/2024/196965PARVOVIRUS COMPOSITIONS AND RELATED METHODS FOR GENE THERAPY
WO - 26.09.2024
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
 Appl.No PCT/US2024/020608 Applicant CARBON BIOSCIENCES, INC. Inventor KOTIN, Robert
The present disclosure provides technologies comprising parvovirus compositions, preparations, constructs, and methods for gene therapy.
6.WO/2024/197310PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS
WO - 26.09.2024
Int.Class A61K 47/54
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
 Appl.No PCT/US2024/021352 Applicant MODERNATX, INC. Inventor SEEPERSAUD, Mohindra
Provided herein are targeting compounds (e.g., a compound of Formula I, a stereoisomer thereof, a tautomer thereof, and/or a pharmaceutically acceptable salt thereof), lipid nanoparticle (LNP) compositions comprising such targeting compounds and the use thereof. The LNP compositions described herein may further comprise one or more selected from ionizable lipids, PEG-lipids, phospholipids, and structural lipids.
7.WO/2024/197242PROTOPARVOVIRUS COMPOSITIONS COMPRISING A PROTOPARVOVIRUS VARIANT VP1 CAPSID POLYPEPTIDE AND RELATED METHODS
WO - 26.09.2024
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
 Appl.No PCT/US2024/021126 Applicant CARBON BIOSCIENCES, INC. Inventor KOTIN, Robert
The present disclosure provides technologies comprising compositions, preparations, constructs, and methods comprising a protoparvovirus variant VP1 capsid polypeptide.
8.WO/2024/192257MRNA THERAPEUTICS FOR DISORDERS OF VASCULAR PERMEABILITY
WO - 19.09.2024
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
 Appl.No PCT/US2024/019965 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor PARHIZ, Hamideh
The present invention relates to compositions and methods for pulmonary targeted delivery of VE-cadherin and methods of use thereof for treating or preventing vascular permeability disorders, such as acute respiratory stress syndrome (ARDS).
9.WO/2024/192351TRANSIENT MODIFIED-RNA BASED ELEVATED EXPRESSION OF FLI-1 TO AUGMENT HEMATOPOIETIC STEM AND PROGENITOR CELL EXPANSION
WO - 19.09.2024
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
 Appl.No PCT/US2024/020161 Applicant CORNELL UNIVERSITY Inventor ITKIN, Tomer
The present disclosure is directed to a method of activation and expansion of adult non-activated hematopoietic stem and progenitor cells (HSPCs). The present disclosure reveals that Fli-1 activity is essential during regenerative hematopoiesis. Fli-1 directs activation programs while manipulating cellular sensory and output machineries, enabling HSPCs co-adoptability with a stimulated vascular niche. Applying FLI-1 transient modified-mRNA transduction into lethargic adult human mobilized HSPCs, enables their niche-mediated expansion and superior engraftment capacities. The present disclosure provides a population of regenerated and expanded adult hematopoietic stem and progenitor cells (HSPCs). The present disclosure also provides methods of treating a subject in need of activated and expanded adult HSPCs by administering the regenerated and expanded HSPCs to the subject.
10.WO/2024/192233TARGETED DELIVERY OF THERAPEUTIC AGENTS TO THE CENTRAL NERVOUS SYSTEM AND METHODS OF USE FOR TREATMENT OF NEUROLOGICAL CONDITIONS
WO - 19.09.2024
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2024/019916 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor BRENNER, Jacob, S.
The present invention relates to compositions and methods for targeted delivery of therapeutic anti-inflammatory agents to the blood brain barrier to restore blood brain barrier function. The delivery method can comprise various nanoparticles. The invention also relates to methods of treating or preventing neurological conditions using the described compositions. The compositions can include use of cell editing processes such as CRISPR/Cas systems.
# -